Natural Killer Cells: Tolerance to Self and Innate Immunity to Viral Infection and Malignancy

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages S97-S105

  Yokoyama, Wayne M ^a   Altfeld, Marcus ^b   Hsu, Katharine C ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY A; NATURAL KILLER CELL RECEPTOR;

ARTICLE; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; SOLID MALIGNANT NEOPLASM; TREATMENT OUTCOME; VIRUS INFECTION; ANIMAL; HISTOCOMPATIBILITY; IMMUNOLOGY; NEOPLASM; REVIEW;

ANIMALS; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; NEOPLASMS; RECEPTORS, NATURAL KILLER CELL; SELF TOLERANCE; TRANSPLANTATION IMMUNOLOGY; VIRUS DISEASES;

EID: 77953032756     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.10.009     Document Type: Article

References (84)

1. Karre, K., Ljunggren, H.G., Piontek, G., et al. Selective rejection of H-2-deficient lymphoma variants suggests an alternative immune defence strategy. Nature 319 (1986), 675–678.
2. Lanier, L., NK cell recognition. Annu Rev Immunol 23 (2005), 225–274.
3. Alcami, A., Koszinowski, U.H., Viral mechanisms of immune evasion. Immunol Today 21 (2000), 447–455.
4. Algarra, I., Garcia-Lora, A., Cabrera, T., et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53 (2004), 904–910.
5. Long, E.O., Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 17 (1999), 875–904.
6. Barten, R., Torkar, M., Haude, A., et al. Divergent and convergent evolution of NK cell receptors. Trends Immunol 22 (2001), 52–57.
7. Yawata, M., Yawata, N., Draghi, M., et al. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK cell repertoires towards a balance of missing-self response. Blood 112 (2008), 2369–2380.
8. Pascal, V., Stulberg, M., Anderson, S., Regulation of class I major histocompatibility complex receptor expression in natural killer cells: one promoter is not enough. Immunol Rev 914 (2006), 9–21.
9. Bashirova, A., Martin, M., McVicar, D., et al. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genom Hum Genet 7 (2006), 277–300.
10. Makrigiannis, A.P., Pau, A.T., Schwartzberg, P.L., et al. A BAC contig map of the Ly49 gene cluster in 129 mice reveals extensive differences in gene content relative to C57BL/6 mice. Genomics 79 (2002), 437–444.
11. Groh, V., Bahram, S., Bauer, S., et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointenstinal epithelium. Proc Natl Acad Sci USA 93 (1996), 12445–12450.
12. Liao, N.S., Bix, M., Zijlstra, M., et al. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253 (1991), 199–202.
13. Kim, S., Poursine-Laurent, J., Truscott, S., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436 (2005), 709–713.
14. Yokoyama, W., Kim, S., Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 214 (2006), 143–154.
15. Anfossi, N., Andre, P., Guia, S., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006), 331–342.
16. Yu, J., Heller, G., Chewning, J., et al. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and -HLA-C ligands. J Immunol 179 (2007), 5977–5989.
17. Yawata, M., Yawata, N., Draghi, M., et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 203 (2006), 633–645.
18. Johansson, S., Johansson, M., Rosmaraki, E., et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med 201 (2005), 1145–1155.
19. Joncker, N., Fernandez, N., Treiner, E., et al. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol 182 (2009), 4572–4580.
20. Fernandez, N., Treiner, E., Vance, R., et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105 (2005), 4416–4423.
21. Sun, J., Lanier, L., Cutting edge: viral infection breaks NK cell tolerance to “missing self.”. J Immunol 181 (2008), 7453–7457.
22. Peterson, M.E., Long, E.O., Inhibitory receptor signaling via tyrosine phosphorylation of the adaptor Crk. Immunity 29 (2008), 578–588.
23. Kim, S., Iizuka, K., Kang, H., et al. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol 3 (2002), 523–528.
24. Dorfman, M., Raulet, D., Acquisition of Ly49 receptor expression by developing natural killer cells. J Exp Med 187 (1998), 609–618.
25. Grzywacz, B., Kataria, N., Sikora, M., et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108 (2006), 3824–3833.
26. Ioannidis, V., Zimmer, J., Beermann, F., et al. Cre recombinase-mediated inactivation of H-2D(d) transgene expression: evidence for partial missing self-recognition by Ly49A NK cells. J Immunol 167 (2001), 6256–6262.
27. Wu, M., Raulet, D., Class I-deficient hemopoietic cells and nonhemopoietic cells dominantly induce unresponsiveness of natural killer cells to class I-deficient bone marrow cell grafts. J Immunol 158 (1997), 1628–1633.
28. Roth, C., Carlyle, J., Takizawa, H., et al. Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity 13 (2000), 143–153.
29. Williams, N., Kubota, A., Bennett, M., et al. Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression. Eur J Immunol 30 (2000), 2074–2082.
30. Vosshenrich, C., Garcia-Ojeda, M., Samson-Villeger, S., et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 7 (2006), 1217–1224.
31. Cheng, M., Charoudeh, H., Brodin, P., et al. Distinct and overlapping patterns of cytokine regulation of thymic and bone marrow-derived NK cell development. J Immunol 182 (2009), 1460–1468.
32. Doucey, M., Scarpellino, L., Zimmer, J., et al. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol 5 (2004), 328–336.
33. Fourmentraux-Neves, E., Jalil, A., Rocha, S.D., et al. Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells. Blood 112 (2008), 2381–2389.
34. Ho, E., Cayannopoulos, L., Poursine-Laurent, J., et al. Co-stimulation of multiple NK cell activation receptors by NKG2D. J Immunol 169 (2002), 3667–3675.
35. Bryceson, Y., March, M., Ljunggren, H., et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107 (2006), 159–166.
36. Wang, L., Chu, D., Dokun, A., et al. Inducible expression of the gp49B inhibitory receptor on NK cells. J Immunol 164 (2000), 5215–5220.
37. Groh, V., Wu, J., Yee, C., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002), 734–738.
38. Tripathy, S., Keyel, P., Yang, L., et al. Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J Exp Med 205 (2008), 1829–1841.
39. Coudert, J., Scarpellino, L., Gros, F., et al. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 111 (2008), 3571–3578.
40. Ferlazzo, G., Tsang, M., Moretta, L., et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 195 (2002), 343–351.
41. Fernandez, N., Lozier, A., Flament, C., et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5 (1999), 405–411.
42. Gerosa, F., Baldani-Guerra, B., Nisii, C., et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195 (2002), 327–333.
43. Biron, C., Byron, K., Sullivan, J., Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320 (1989), 1731–1735.
44. Orange, J., Ramesh, N., Remold-O'Donnell, E., et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci USA 99 (2002), 11351–11356.
45. Orange, J., Turvey, K.S.S., Krzewski, K., The Wiskott-Aldrich syndrome. Cell Mol Life Sci 61 (2004), 2361–2385.
46. Martin, M.P., Gao, X., Lee, J.H., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31 (2002), 429–434.
47. Alter, G., Martin, M., Teigen, N., et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 204 (2007), 3027–3036.
48. Long, B., Ndhlovu, L., Oksenberg, J., et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 82 (2008), 4785–4792.
49. Alter, G., Rihn, S., Walter, K., et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol 83 (2008), 6798–6805.
50. Boulet, S., Sharafi, S., Simic, N., et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 22 (2008), 595–599.
51. Collins, K., Chen, B., Kalams, S., et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391 (1998), 397–401.
52. LeGall, S., Erdtmann, L., Benichou, S., et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8 (1998), 483–495.
53. Cohen, G., Gandhi, R., Davis, D., et al. The selective down-regulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10 (1999), 661–671.
54. Nattermann, J., Nischalke, H., Hofmeister, V., et al. HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther 10 (2005), 95–107.
55. Hansasuta, P., Dong, T., Thananchai, H., et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 34 (2004), 1673–1679.
56. Malnati, M., Peruzzi, M., Parker, K., et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 267 (1995), 1016–1018.
57. Mandelboim, O., Wilson, S., Vales-Gomez, M., et al. Self and viral peptides can initiate lysis by autologous natural killer cells. Proc Natl Acad Sci USA, 94, 1997 6404–4609.
58. ∗2705 by specific natural killer cells. J Immunol 157 (1996), 3350–3356.
59. ∗2705. J Exp Med 184 (1996), 1585–1590.
60. Rajagopalan, S., Long, E., The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med 185 (1997), 1523–1528.
61. ∗0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc Natl Acad Sci USA 94 (1997), 6313–6318.
62. Blanc, K.L., Remberger, M., Barrett, J., Lymphocyte recovery is a major determinant of transplant outcome after myeloablative transplantation in patients with myeloid malignancies receiving matched unrelated stem cell allografts [abstract]. Biol Blood Marrow Transplant, 15, 2009, 27.
63. Chang, Y., Zhao, X., Huang, X., Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 14 (2008), 323–334.
64. Ruggeri, L., Capanni, M., Urbani, E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002), 2097–2100.
65. Ruggeri, L., Capanni, M., Casucci, M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999), 333–339.
66. Stern, M., Ruggeri, L., Capanni, M., et al. Human leukocyte antigens A23, A24 and A32 but not A25 are ligands for KIR3DL1. Blood, 2008;May 23 [Epub ahead of print].
67. Foley, B., Santis, D.D., Beelen, E.V., et al. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 112 (2008), 435–443.
68. Ruggeri, L., Mancusi, A., Capanni, M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110 (2007), 433–440.
69. Yabe, T., Matsuo, K., Hirayasu, K., et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 14 (2008), 75–87.
70. Hsu, K., Gooley, T., Malkki, M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 12 (2006), 828–836.
71. Hsu, K., Keever-Taylor, C., Wilton, A., et al. Improved outcome in allogeneic hematopoietic stem cell transplantation in acute myelogenous leukemia (AML) predicted by donor KIR genotype and recipient HLA genotype in T-cell-depleted HLA-identical sibling transplants. Blood 105 (2005), 4878–4884.
72. Miller, J., Cooley, S., Parham, P., et al. Missing KIR ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109 (2007), 5058–5061.
73. Clausen, J., Wolf, D., Petzer, A., et al. Impact of natural killer cell dose and donor killer cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 148 (2007), 520–528.
74. Sobecks, R., Ball, E., Maciejewski, J., et al. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 39 (2007), 417–424.
75. Yu, J., Venstrom, J., Liu, X., et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T-cell-depleted allogeneic hematopoietic cell transplantation. Blood 113 (2009), 3875–3884.
76. Chen, C., Busson, M., Rocha, V., et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell-depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 38 (2006), 437–444.
77. Verheyden, S., Schots, R., Duquet, W., et al. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19 (2005), 1446–1451.
78. Pende, D., Marcenaro, S., Falco, M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113 (2009), 3119–3129.
79. Cooley, S., Trachtenberg, E., Bergemann, T., et al. Donors with group B haplotypes improve relapse-free survival after unrelated hemaotpoietic transplantation for acute myeloid leukemia. Blood 113 (2009), 726–732.
80. Venstrom, J., Gooley, T., Spellman, S., et al. Donor KIR 3DS1 is associated with less acute GVHD following unrelated allogeneic hematopoietic cell transplantation for hematologic malignancies [abstract]. Biol Blood Marrow Transplant, 2009.
81. Cook, M., Briggs, D., Craddock, C., et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell-replete stem cell transplantation. Blood 107 (2006), 1230–1232.
82. Pergam, S., Boeckh, M., Hsu, K., et al. Donor 3DS1 is associated with less CMV disease following unrelated hematopoietic cell transplantation in high-risk subjects [abstract]. Interscience Conference on Antimicrobial Agents and Chemotherapy, 2009.
83. Leung, W., Handgretinger, R., Iyengar, R., et al. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 97 (2007), 539–542.
84. Venstrom J, Zheng J, Noor N, et al. KIR and HLA genotypes are associated with improved survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res., in press.